A. S. Jung

发表

Autologous hematopoietic stem cell transplantation as an intensive consolidation therapy for adult patients in remission from acute myelogenous leukemia.

K. Messer, Minya Pu, J. Castro, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Analysis of KRAS/NRAS mutations in phase 3 study 20050181 of panitumumab (pmab) plus FOLFIRI versus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).

E. Van Cutsem, F. Lordick, C. Punt, 2014 .

Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer

A. Bardelli, E. Van Cutsem, J. Tabernero, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab (pmab) plus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).

F. Lordick, C. Punt, M. Ducreux, 2014 .

Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer

Marc Peeters, Hua Yu, Gregory Wilson, 2015, Clinical Cancer Research.

Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer.

Gary Middleton, Takayuki Yoshino, Chloe E Atreya, 2018, Cancer discovery.

2184 A phase 2 study of mechanisms of acquired resistance to panitumumab (pmab) plus irinotecan (iri) for metastatic colorectal cancer (mCRC)

A. Bardelli, J. Tabernero, M. Boedigheimer, 2015 .

Long-Term Follow-up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

S. de Vos, D. Maloney, I. Yakoub-Agha, 2021, Blood.

Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma

G. Verhoef, J. Franklin, K. Mason, 2018, Leukemia & lymphoma.

Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma

J. Gribben, J. Radford, M. Brookhart, 2022, Blood.

Tensin2 is a novel mediator in thrombopoietin (TPO)-induced cellular proliferation by promoting Akt signaling

G. MacBeath, K. Kaushansky, A. Kaushansky, 2011, Cell cycle.

A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer

Joon-Oh Park, Tae Won Kim, C. Lofton-Day, 2016, British Journal of Cancer.

A Phase 1/1b tolerability study of rilotumumab alone or in combination with cisplatin and capecitabine in Japanese patients with gastric cancer

K. Muro, Yilong Zhang, T. Nakajima, 2017, Japanese journal of clinical oncology.

Clinical validation of the next-generation sequencing-based Extended RAS Panel assay using metastatic colorectal cancer patient samples from the phase 3 PRIME study

J. Douillard, C. Lofton-Day, M. Peeters, 2018, Journal of Cancer Research and Clinical Oncology.

Final Analysis of Outcomes and RAS/BRAF Status in a Randomized Phase 3 Study of Panitumumab and Best Supportive Care in Chemorefractory Wild Type KRAS Metastatic Colorectal Cancer

Joon-Oh Park, Tae Won Kim, C. Lofton-Day, 2018, Clinical colorectal cancer.

A Comparison of Clinical Outcomes from Updated Zuma-5 (Axicabtagene Ciloleucel) and the International Scholar-5 External Control Cohort in Relapsed/Refractory Follicular Lymphoma (R/R FL)

J. Gribben, J. Radford, C. Jacobson, 2021, Blood.

Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma

G. Verhoef, J. Franklin, K. Mason, 2020, Leukemia & lymphoma.